Şunu aradınız:: acetilkolinesteraze (Hırvatça - İngilizce)

in vitro ovaj metabolit pokazuje minimalnu inhibiciju acetilkolinesteraze (<10%).
in vitro, this metabolite shows minimal inhibition of acetylcholinesterase (<10%).

in vitro, taj metabolit pokazuje minimalnu inhibiciju acetilkolinesteraze (<10 %).
in vitro, this metabolite shows minimal inhibition of acetylcholinesterase (<10 %).

rivastigmin je inhibitor acetilkolinesteraze i butirilkolinesteraze karbamatnog tipa, za kojeg se smatra da olakšava kolinergičku neurotransmisiju usporavanjem razgradnje acetilkolina kojeg otpuštaju funkcionalno intaktni kolinergički neuroni.
rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones.

s obzirom na to da je poluvijek rivastigmina u plazmi oko l sat, a trajanje inhibicije acetilkolinesteraze oko 9 sati, preporučuje se da se u slučajevima asimptomatskog predoziranja u iduća 24 sata ne daju daljnje doze rivastigmina.
as rivastigmine has a plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose no further dose of rivastigmine should be administered for the next 24 hours.

s obzirom na to da je poluvijek rivastigmina u plazmi oko 3,4 sata, a trajanje inhibicije acetilkolinesteraze oko 9 sati, preporučuje se da se u slučajevima asimptomatskog predoziranja svi exelon transdermalni flaster moraju se odmah ukloniti i novi se transdermalni flaster ne smije primijeniti sljedeća 24 sata.
as rivastigmine has a plasma half-life of about 3.4 hours and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose all exelon transdermal patches should be removed immediately and no further transdermal patch should be applied for the next 24 hours.

u zdravih, mladih muškaraca oralna doza od 3 mg smanjuje aktivnost acetilkolinesteraze (ache) u cerebrospinalnoj tekućini za približno 40% unutar prvih 1,5 sati nakon primjene.
in healthy young men, an oral 3 mg dose decreases acetylcholinesterase (ache) activity in csf by approximately 40% within the first 1.5 hours after administration.

metaanaliza bolesnika s umjerenom do teškom alzheimerovom bolešću (ukupni mmse <20) iz šest faza iii placebom kontroliranih ispitivanja u trajanju od 6 mjeseci (uključujući monoterapijska ispitivanja i ispitivanja s bolesnicima na stabilnoj dozi inhibitora acetilkolinesteraze) pokazala je da postoji statistički značajan učinak u korist liječenja memantinom u kognitivnom, globalnom i funkcionalnom području.
a meta-analysis of patients with moderate to severe alzheimer’s disease (mmse total scores < 20) from the six phase iii, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.